HRA® conducted a study to analyze the infectious disease landscape and scope for areas of opportunities for drug development, product marketing, and physician education. Use this syndicated study to strategically guide your entrance into this space and target infectious disease specialists.
Recent legislation has provided a faster path to market for biosimilars which are positioned to revolutionize the field of protein therapeutics. HRA® analyzed clinical, regulatory, and survey information on biosimilars to improve understanding and future expectations in the field. HRA® conducted an online survey with 160 Rheumatologists and Oncologists designed to yield insights into potential drivers of biosimilar prescribing. In addition, key insights from payers were included.
HRA® conducted a syndicated study to analyze the primary care physican (PCP) percieved involvement in cancer care. In this study, HRA® touched all facets of the relationship between PCPs and oncology from EMRs, early referrals and how to ensure both parties are informed to better the relationship between pharma, cancer centers,and PCPs.
HRA's Oncology Pathways: Future of Incentive-Driven Adherence explores recent decisions by payers to provide financial incentives to oncologists to follow their evidence-based treatment pathways. This creates an opportunity for pharmaceutical companies to understand the implications this may have on current brand utilization and future prescribing trends.
It is clear that, in addition to clinical factors, oncologists make many treatment decisions based on their own attitudes, individual patient circumstances and emotions. Use the insights from this syndicated report to determine which factors drive healthcare professionals to prescribe your drug and also guide your discussions with them.
This comprehensive investigation sources KOLs, community oncologists, and more to uncover actionable insights. There are multiple new checkpoint inhibitors that have entered the market with their own companion biomarkers; different sets of PD-L1 scores and efficacy parameters. How will these biomarker assays be used and affect current treatment decisions?